在现场聚合介导的抗原呈现
Chao Pan1, Lu Wang1, Mengmeng Zhang1
1Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine, Institute of Molecular Medicine, State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.
一种新的局部聚合介导抗原呈现 (IPAP) 方法通过将纳米疫苗固定在树突细胞上来增强适应性免疫力. 这种方法改善了抗原呈现,并引起了强大的免疫反应来免疫疾病.
科学领域:
- 免疫学
- 纳米技术
- 生物材料
背景情况:
- 适应性免疫依赖于有效的抗原呈现细胞激活.
- 常规策略通常显示低于最佳的抗原特异性原始化.
- 需要改进的方法来增强抗原呈现和免疫反应.
研究的目的:
- 开发和评估在现场聚合介导的抗原呈现 (IPAP) 以增强适应性免疫力.
- 研究IPAP改善树突细胞抗原呈现的机制.
- 评估IPAP在引起针对瘤和病毒抗原的特异性免疫反应中的有效性.
主要方法:
- 通过局部多巴胺聚合形成的带抗原的纳米疫苗的开发.
- 纳米疫苗在体内固定在树突细胞上.
- 对抗原吸收,降解和呈现的评估.
- 在小鼠模型中评估免疫反应,包括细胞和幽默免疫.
- 使用卵泡蛋白和SARS-CoV-2尖端蛋白S1亚单元测试IPAP.
主要成果:
- IPAP自发地形成纳米疫苗,在体内固定在树突细胞上.
- 化学结合的纳米疫苗增强了巨细胞分裂并减少了抗原降解.
- IPAP延长了注射部位的抗原保留时间,并改善了淋巴结的积累.
- 对表达卵蛋白的瘤观察到显著的保护性免疫力.
- 使用SARS-CoV-2尖端蛋白S1亚单元实现了S1特异性免疫球蛋白G的增加.
结论:
- IPAP提供了一种简单多用途的激发抗原呈现细胞的策略.
- 这种方法有效地增强了抗原特异性适应性免疫反应.
- IPAP提供了一种对各种疾病的免疫方法.
更多相关视频
08:37In Situ MHC-tetramer Staining and Quantitative Analysis to Determine the Location, Abundance, and Phenotype of Antigen-specific CD8 T Cells in Tissues
Published on: September 22, 2017
07:18HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL
Published on: April 11, 2011
相关概念视频
Antigen Presenting Cells
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...
Antigen Processing Pathways
MHC Class I: Presenting Endogenous...
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and...
Cell-mediated Immune Responses
Diversity of Antigen Receptors
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
